| ||||||||
|
Bayer AGwww.bayer.com (malaria treatment info)GBC Member since March 2003Location: WorldwideBayer promotes the distribution of insecticide-treated bed nets that provide effective protection against deadly mosquito bites. The company supports aid organizations such as the Red Cross, the World Health Organization (WHO), UNICEF, USAID, Population Services and the Global Fund to Fight AIDS, Tuberculosis and Malaria by making available these protective mosquito nets and the necessary insecticide impregnation sets. Donations are supplemented by comprehensive information and education projects. In order to develop new vector control solutions to help protect against malaria, Bayer has been appointed as a potential partner in a public-private partnership project that has received US$ 50.7 million in funding from the Bill & Melinda Gates Foundation. 
Becton, Dickinson and Companywww.bd.comGBC Member since August 2003Location: GlobalBD has responded to the needs of those affected by diseases such as HIV/AIDS and TB by focusing its efforts in four key areas: increasing access to critical technologies, building healthcare capacity in developing countries, investing in new technologies and volunteerism and philanthropy. Within each of these areas BD has collaborated with both the private and public sector to create sustainable programs that effectively address these diseases. BD is now applying these same efforts to fighting malaria, by investing in a new rapid diagnostic test to detect the most deadly strain, Malaria falciparum. This test is currently undergoing clinical trials in Uganda. The Company is also planning to collaborate on a study with the Millennium Villages Project in Rwanda to determine the best use of diagnostic technology in an overall national malaria program. An important first step in building health systems capacity in Africa is increasing access to basic diagnosis. Diagnostic testing is used as a quality control to know when drugs should be administered and whether they are working. The absence of diagnostics can lead to the inappropriate provision of medications, which, in turn, can lead to drug resistance. With resistance to malaria drugs increasing, BD is committed to improving the state of malaria diagnostics. 
BHP Billitonwww.bhpbilliton.comGBC Member since May 2003Location: Mozambique, South Africa and SwazilandThe partnership between BHP Billiton, three regional governments and international organizations, has shown enormous success in tackling malaria — one of Africa's most recurrent and deadly issues. Through its efforts, BHP Billiton has assisted in reducing malaria deaths by some 80% in southern Africa. The program is classic partnership between the private sector and the public sector, but it is also a partnership between three countries to ensure regional success. As the program gathers momentum (the Global Fund awarded this regional initiative US$22 million over five years), it will move into initiatives to strengthen research and development. The keys to success have been funding, good project management and speedy implementation all managed via the partnership approach. African researchers apply best practice and overcome obstacles to development. To learn more click here to read the full brochure [.pdf - 2,600kb] 
BPwww.bp.com (malaria control info)GBC Member since July 2002Location: Zambia and AngolaIn Zambia, BP has joined forces with Konkola Mines to launch a Roll Back Malaria campaign. The objective is to eradicate the disease in five mining towns in the country's Copperbelt. The project is worth $560,000 over two years, of which BP is contributing $60,000. Local homes are being sprayed with insecticide to destroy malaria-carrying mosquitoes, while grass is being cut and storm water drains cleared to reduce potential breeding grounds. Insecticide-treated bed nets are also being distributed to vulnerable groups, including people in clinics and children in orphanages. Alongside these practical preventative measures, people living in local communities are also being taught how to maintain clean, mosquito-free living environments. In Angola, BP operates a malaria-management program to reduce the risk of infection to its employees. This includes educational initiatives to make people more aware of the health risks the disease presents, along with practical advice about how to avoid mosquito bites, what medication to use in case of infection and how to ensure early diagnosis and effective treatment. BP is also working with OGP and IPIECA, representing the oil and gas industry, in the production of global guidelines on malaria management and control. These guidelines will recommend a hierarchy of interventions from vector control to chemoprophylaxis, with the emphasis on combinations of interventions rather than just chemoprophylaxis. 
Chevronwww.chevron.comGBC Member since December 2001Location: AfricaChevron has programs in place to fight malaria in areas of Africa where the disease is a major health threat to the company's employees, their families and the communities in which they live. Anti-malarial programs targeting both prevention and treatment have been strengthened, and communication efforts enhanced in Angola and Nigeria, particularly as they affect children. In addition, Chevron is collaborating with several companies to fight malaria, including through the Corporate Alliance on Malaria in Africa (CAMA). CAMA, formed in 2006, will be working with the Global Health Initiative of the World Economic Forum to implement the initiative's activities on behalf of the corporate partners. 
Deutsche Post World Netwww.dpwn.deGBC Member since September 2005Location: KenyaIn 2006, Deutsche Post World Net expanded its existing strategic partnership with the United Nations by announcing a new partnership with UNICEF to reduce child mortality worldwide. As a first step, DHL helped distribute approximately 3.5 million insecticide-treated bed nets to children under five in Kenya. Deutsche Post World Net also supports UNICEF's mission in Kenya with additional in-kind and financial contributions. For example, DHL is undertaking an in-depth analysis of UNICEF's medical logistics processes in the Kwale region of Kenya. Deutsche Post World Net employees will also support UNICEF's efforts in Kenya with both individual donations and group fundraising events. Monies raised will be used to purchase additional malaria bed nets for children, as well as to fund health and education projects. Additionally, employee volunteers will support UNICEF Kenya on-site in selected health and education campaigns in the Kwale region. Deutsche Post World Net's partnership with UNICEF will be extended to other countries on a step-by-step basis building on the experience gained in Kenya. 
GlaxoSmithKlinewww.gsk.comGBC Member since July 2001*Location: Global*GSK was a founding member of GBC's predecessor the Global Business Council on HIV/AIDS. Sir Richard Sykes, Chairman of Glaxo Wellcome at that time was the first Chairman of the Global Business Council on HIV/AIDS. Research & Development Discovery Research: Malaria research is conducted at GSK's dedicated Diseases of the Developing World drug discovery unit at Tres Cantos in Spain, in partnership with the Medicines for Malaria Venture (MMV). Current work includes isoquine and a novel class of compounds termed pyridones. Clinical development: CDA is a fixed-ratio artemisinin combination therapy (ACT) of chlorproguanil hydrochloride + dapsone + artesunate in phase III clinical development. It is being developed in partnership with the WHO-TDR, MMV, UNICEF/UNDP/World Bank, the University of Liverpool and the London School of Hygiene and Tropical Medicine. Vaccines: GSK Biologicals is developing the world's most advanced malaria vaccine candidate, which was shown to be 58% effective in preventing severe disease in one-to-four year-olds in a groundbreaking proof-of-concept study conducted in Mozambique in 2004. In partnership with PATH's Malaria Vaccine Initiative, GSK is moving the vaccine candidate, which is known as RTS,S, into advanced clinical trials in several African countries. Supporting Access GSK has offered its vaccines to developing world public healthcare programs at preferential prices for over 20 years, and this approach will also be adopted for a future malaria vaccine. Its anti-malarial medicines are available to public healthcare programs in over 60 developing world countries at preferential, not-for-profit prices. This commitment covers both existing and future anti-malarial drug products. The GlaxoSmithKline African Malaria Partnership (AMP) The AMP is part of GlaxoSmithKline's global charitable program focusing on health and education in under-served communities around the world. The AMP was established in 2001 to support effective community-focused responses to improve the prevention and treatment of malaria in sub-Saharan Africa. Since its inception, the AMP has worked with a number of not-for-profit organizations in eight African countries to implement behavior change programs to improve the prevention and treatment of malaria, in vulnerable communities totaling over 2 million people. In November 2005, the program was extended to support a new advocacy initiative — Mobilizing for Malaria — in partnership with the Malaria Consortium. Mobilizing for Malaria is raising awareness of malaria in Europe and throughout Africa to bring greater resources to bear against the disease. Learning from the success of advocacy programs that brought HIV/AIDS to the world's attention, the initiative engages politicians, the media and the general public in order to tackle this tragedy. In Europe, the program focuses on the United Kingdom, France and Belgium — the countries with the strongest ties to Africa. In Africa, the focus is on Ethiopia (and the African Union), Cameroon, and other countries in Eastern, Western, and Central Africa. 
JN International Medical Corporationwww.jnii-usa-bharat.comGBC Member since January 2006Location: AfricaThe United States-based JN-International Medical Corporation opened its first overseas branch in 2005 in Abidjan, Côte d'Ivoire and later in 2006 in Ouagadougou, Burkina Faso. Operating in Africa enables the company to more efficiently store and distribute many of its products. By February 2007, the company plans to supply two million diagnostic tests for Malaria and TB to West Africa. JN markets the most acceptable malaria rapid diagnostic test kit in Africa, which detects the antigens of lactate dehydrogenase (pLDH) and can differentiate between malaria caused by P. falciparum and that caused by P. vivax, P. malariae, and P. ovale. This pLDH test has a sensitivity of 96% and a specificity of 98.5%, confirmed by Pasture Research Institutes in Ivory Coast and in Madagascar. The ability to accurately diagnose malaria is the first step in being able to help those infected. JN-International Medical Corporation has a complete selection of rapid diagnostics available for export from the United States. 
Lafargewww.lafarge.comGBC Member since January 2002Location: Kenya, Uganda, Malawi, Zambia, Benin, Nigeria, Tanzania, Cameroon, and ZimbabweBeginning in late 2005, Lafarge initiated comprehensive anti-malaria programs in seven African countries, which include prevention and treatment. Lafarge has developed a road map for its work that is based on the company's experience with HIV/AIDS. The company developed a Malaria Toolbox, which includes prevention through an awareness program, distribution of insecticide-treated bednets (ITN), intermittent preventative treatment (IPT) and indoor residual spraying (IRS). Treatment is provided with Artemisinin Combination Therapies (ACTs) following microscopic diagnosis and rapid tests. 
Novartis AGwww.novartis.comGBC Member since August 2004Location: GlobalIn September 2006, Novartis reduced the average price of its antimalarial medicine, Coartem, by more than one-third to an average of one dollar per treatment in an effort to accelerate access to malaria therapy in low-income regions, particularly Africa. Since 2001, Novartis, in collaboration with the World Health Organization (WHO), has been providing Coartem at no profit. Deliveries for Coartem have steadily climbed over the last two years — from four million treatments in 2004 to an expected 58 million treatments in 2006. 
Pfizerwww.pfizer.comGBC Member since November 2001Location: Ghana, Kenya and SenegalAs part of an estimated 5-year, $3 million/year pilot project, Pfizer is working with its country offices and on-the-ground partners to increase the percentage of patients who seek proper malaria care and enhance the capacity of the informal sector to serve as a vehicle for the effective delivery of anti-malarial medicine. 
Royal Dutch Shellwww.shell.comGBC Member since March 2002Location: NigeriaThe Shell Petroleum Development Company of Nigeria (SPDC) works to curb the spread of malaria in the country's Niger Delta region. The company's malaria control measures have resulted in a significant reduction both in malaria cases and mortality rate. SPDC's malaria working group has successfully coordinated and continuously improves the Regional response to malaria. The company is a working with Africare in a $4.5 million partnership to roll back the disease in 55 communities in Nigeria. Deploying an integrated malaria control program is a business priority to prevent illness, death and employee absenteeism. 
Sumitomo Chemicalwww.sumitomo-chem.co.jp/english/GBC Member since March 2007Location: Japan, AfricaThe Sumitomo Chemical Group includes some 100 companies operating around the world in six business sectors: basic chemicals, petrochemicals and plastics, fine chemicals, IT-related chemicals, agricultural chemicals, and pharmaceuticals. Although Sumitomo Chemical has diversified its operations over the years to keep abreast of the changing times, the company maintains the basic policy that its operations must not only profit itself but must also benefit society at large. Sumitomo Chemical's commitment to supporting Africa's fight against malaria Conquering malaria is a major challenge for the developing world. In Africa, a child dies from malaria at least every 30 seconds - there are over one million deaths per year from this preventable disease, with consequent huge negative social and economic impact. Long-Lasting Insecticidal Nets (LLINs) are proven, effective tools in the fight against malaria. Sumitomo Chemical has harnessed its considerable development resources to produce the unique Olyset® net, which reduces malaria incidence by preventing blood feeding of malaria-carrying Anopheles mosquitoes. The first LLIN to be recommended by the World Health Organization, the Olyset net is tough, durable and wash-proof. Insecticide is incorporated within the net's fibres during manufacture, for slow release over a sustained period of time. Consequently, Olyset nets never need re-treatment with insecticide, and are guaranteed to be effective for a minimum of five years. Previously, nets needed to be re-treated every 6 months. Various studies have shown that the majority of users fail to re-treat nets - Olyset overcomes this problem. In field tests, Olyset has been shown to still be effective after seven years. Sumitomo Chemical has established large-scale production of Olyset nets to meet the surge in global demand for LLIN technology. Production capacity is currently almost 20 million nets per annum, and will increase to 30 million in 2007. Olyset nets are sold to publicly funded health agencies at lowest cost, under Sumitomo Chemical's corporate social responsibility program. Because Sumitomo Chemical is committed to sustainable development, manufacturing of Olyset nets emphasises local job creation and business partnerships in Africa. Production of Olyset nets started in Arusha, Tanzania in 2003 through A to Z Textiles, an established local company. A royalty-free technology license from Sumitomo Chemical and additional funding from the Acumen Fund led to 1,000 new jobs and annual production of 3 million Olyset nets. Late in 2005, Sumitomo Chemical announced a new joint venture with the owners of A to Z. A new Olyset production facility built on a green field site is the goal. Approximately 1200 additional employees operating extruders, knitting and sewing machines are planned for. With assistance from the Tanzanian Government, electricity and water has been supplied to the new site, and a new road to service the facility is currently under construction. This factory will be the largest employer in Arusha, and one of the largest in Africa. Total annual Olyset net production capacity in Tanzania will be over 8 million nets once the facility is fully operational, in 2007. In addition, providing practical and charitable aid is integral to Sumitomo's philosophy. Sumitomo Chemical has committed over 330,000 Olyset LLINs (worth approximately $2m) to the Millennium Villages project in Africa; these nets will help protect around half a million people against the threat of malaria. The Millennium Villages project provides impoverished African villages with proven, practical technologies that will allow them to function without the debilitating burden of disease and become selfsustaining. Millennium Villages have been established in 10 different countries across sub-Saharan Africa. Initial research will establish the baseline prevalence of malaria in the villages. Further tests will then be conducted after 2 years and 5 years, with simultaneous research on the number of households reporting malaria incidence and regular, random blood tests for malaria. It is anticipated that the use of Olyset LLINs, which are proven to remain effective for the full duration of the evaluation period, will provide significant reduction in malaria incidence. The eradication of malaria requires straightforward commitment and investment. The developed world can help by committing appropriate resources. Disease reduction and life empowerment - through jobs and improved well-being - are achievable. They can save millions of lives and advance quality of life for millions more.
Vestergaard Frandsenwww.vestergaard-frandsen.comGBC Member since November 2006Location: GlobalCommitment to Malaria We are Humanitarian entrepreneurs with a strong commitment to malaria.
Read more about Vestergaard Frandsen's Malaria success stories:
Virgin Unitewww.virginunite.comGBC Member since March 2004Location: South Africa and NigeriaVirgin Unite has launched two new projects targeting TB and Malaria in Africa: South Africa — Bhubezi Community Health Center (HIV, Malaria & TB) The US Government, Virgin Unite, Anglo Coal and the Ndlovu Medical Centre have joined forces in a public-private partnership to build a community health centre adjacent to the Sabi Sands Game Reserve. The vision is to mitigate the effect of HIV/AIDS, which is at pandemic proportions in South Africa, and prevent the devastating impact of TB and Malaria on the community. Through this co-investment scheme, partners are pouring a collective R50 million into creating a 'one-stop health care centre' that will bring free treatment to the community for HIV/AIDS, tuberculosis (TB) and malaria. It will bring doctors, x-ray, pharmacy and laboratory services right into the community and will work together with and in support of neighboring Government clinics. The clinic was launched on 27 October 2006 with Sir Richard Branson, founder of Virgin Unite, the US Ambassador to SA Eric Bost, the CEO of Anglo Coal Ben Magara, and the executive Mayor of Bushbuckridge Councillor Milton Morema. To learn more about the clinic click here to download the press release [.pdf - 28kb] Nigeria — Heaven's Angels (Malaria) Through Heaven's Angels we aim to help stop 10,000 people dying needlessly every day in Sub-Saharan Africa, from diseases such as HIV/AIDS, Malaria and TB. It's is not just about providing medicine — it's about physically getting it to those who need it most. Thousands of people live miles away from medical care and are not easy to reach. Motorcycles are proven to be one of the best methods of delivery and through funds raised by Heaven's Angels we'll be employing local health workers in remote areas to deliver medication, materials and advice to rural communities. The program will initially target Malaria in pilot sites in Nigeria. |
|||||||
